Oak Ridge Investments LLC Sells 854 Shares of Biohaven Ltd. (NYSE:BHVN)

by · The Cerbat Gem

Oak Ridge Investments LLC lowered its position in Biohaven Ltd. (NYSE:BHVN – Free Report) by 3.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 21,146 shares of the company’s stock after selling 854 shares during the period. Oak Ridge Investments LLC’s holdings in Biohaven were worth $1,057,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Algert Global LLC boosted its holdings in Biohaven by 5.9% in the second quarter. Algert Global LLC now owns 7,402 shares of the company’s stock worth $257,000 after acquiring an additional 412 shares in the last quarter. Hsbc Holdings PLC boosted its holdings in Biohaven by 6.1% in the second quarter. Hsbc Holdings PLC now owns 8,291 shares of the company’s stock worth $286,000 after acquiring an additional 480 shares in the last quarter. Canton Hathaway LLC boosted its holdings in Biohaven by 2.3% in the second quarter. Canton Hathaway LLC now owns 21,850 shares of the company’s stock worth $758,000 after acquiring an additional 500 shares in the last quarter. Arizona State Retirement System boosted its holdings in Biohaven by 3.7% in the second quarter. Arizona State Retirement System now owns 20,575 shares of the company’s stock worth $714,000 after acquiring an additional 730 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Biohaven by 4.7% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 17,431 shares of the company’s stock worth $605,000 after acquiring an additional 778 shares in the last quarter. Institutional investors own 88.78% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on BHVN shares. Piper Sandler raised their target price on Biohaven from $66.00 to $76.00 and gave the company an “overweight” rating in a report on Monday, September 23rd. HC Wainwright restated a “buy” rating and issued a $59.00 target price on shares of Biohaven in a report on Tuesday, September 24th. William Blair upgraded Biohaven to a “strong-buy” rating in a report on Friday, August 30th. Jefferies Financial Group started coverage on Biohaven in a report on Monday, September 16th. They issued a “buy” rating and a $57.00 target price on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Biohaven in a report on Wednesday, October 23rd. Thirteen research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $61.92.

Read Our Latest Report on BHVN

Insiders Place Their Bets

In other news, Director John W. Childs bought 21,052 shares of the firm’s stock in a transaction on Wednesday, October 2nd. The stock was acquired at an average cost of $47.50 per share, with a total value of $999,970.00. Following the completion of the transaction, the director now directly owns 21,052 shares of the company’s stock, valued at $999,970. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, Director John W. Childs purchased 21,052 shares of Biohaven stock in a transaction dated Wednesday, October 2nd. The stock was bought at an average cost of $47.50 per share, for a total transaction of $999,970.00. Following the completion of the transaction, the director now owns 21,052 shares in the company, valued at $999,970. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Gregory Bailey purchased 5,000 shares of Biohaven stock in a transaction dated Tuesday, September 24th. The stock was bought at an average price of $44.19 per share, with a total value of $220,950.00. Following the completion of the transaction, the director now owns 1,620,071 shares of the company’s stock, valued at $71,590,937.49. This represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 16.00% of the company’s stock.

Biohaven Stock Down 1.5 %

Shares of BHVN opened at $49.72 on Friday. The stock has a 50 day moving average of $45.50 and a 200 day moving average of $40.08. Biohaven Ltd. has a 12 month low of $25.97 and a 12 month high of $62.21.

Biohaven (NYSE:BHVN – Get Free Report) last released its earnings results on Thursday, August 8th. The company reported ($3.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.72) by ($1.92). Research analysts predict that Biohaven Ltd. will post -8.81 earnings per share for the current year.

Biohaven Company Profile

(Free Report)

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.

Featured Stories